Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia
- 19 December 2024
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (2) , e5-e15
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Ledipasvir/Sofosbuvir in Hepatitis C Virus–Infected Children With Hematological Malignancies: A Pharmacokinetic StudyClinical Therapeutics, 2023
- A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approachCPT: Pharmacometrics & Systems Pharmacology, 2021
- Global prevalence of hepatitis C virus in children in 2018: a modelling studyThe Lancet Gastroenterology & Hepatology, 2020
- Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11Hepatology, 2018
- Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis CClinical Pharmacokinetics, 2016
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Treatment for hepatitis C virus–induced portal hypertension in leukemic childrenMedical Oncology, 2013
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2012
- Hepatic Microcirculation in Fatty Liver DiseaseThe Anatomical Record, 2008
- Management of viral hepatitis in hematologic malignanciesBlood Reviews, 2008